看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。/ \% N: a- O3 E" ~
+ w/ v* E6 M. A" R0 r" T9 Y: X y% @9 c
Currently available feasibility data for possible combination strategies. ! `5 H9 |# O7 l1 l$ a
————————————————————————————————9 |# f) U* }- {/ q, S! \2 v$ c6 g+ `- K
Combination Feasibility according to preliminary data ! E W- o7 g, T% U
——————————————————————————————————
: l! V6 G" p( [/ dBevacizumab + sorafenib Yes, reduced dose
* V' d$ ?* g; @+ R2 YBevacizumab + sunitinib† No ( \# D1 C) _) u! T- F( b
Bevacizumab + temsirolimus Yes + A% p! x) W* i( z
Bevacizumab + everolimus Yes ( B0 Z6 S* M' ~
Sorafenib + sunitinib ?
* H6 u; _- p! k# K# D; ySorafenib + temsirolimus Yes, reduced dose
7 A ?; G* C# X. V8 vSorafenib + everolimus Yes, reduced dose
$ [( {4 G1 @0 c7 e+ F( pSunitinib + temsirolimus† No
. g' |( U9 `$ ^Sunitinib + everolimus ? 6 j \; o$ l5 p+ Z' [/ v
Temsirolimus + everolimus ?
; Z, g O3 o9 D0 F2 q" j+ n————————————————————& K8 t5 T9 c# v
†Led to US FDA warning.
# L4 o }- l) g# \?: As yet unattempted combination.
' L# G; ?1 d* Z8 Y. r7 x |